Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Pancreatic Endocrine Carcinoma

Known as: Islet cell carcinoma, Malignant Pancreatic Endocrine Tumor, High Grade Pancreatic Neuroendocrine Carcinoma 
An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the pancreas. The mitotic count is… Expand
National Institutes of Health

Related topics

Related topics

30 relations
Blood supply aspectsCDISC SEND Tumor Findings Results TerminologyClinical Data Interchange Standards Consortium TerminologyDacarbazine
Expand

Broader (4)

CarcinomaIslet Cell TumorMalignant neoplasm of pancreasPancreatic Neoplasm

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
Multiple angiogenesis inhibitors have been therapeutically validated in preclinical cancer models, and several in clinical trials… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Population-Based Study of Islet Cell Carcinoma
BackgroundWe examine the epidemiology, natural history, and prognostic factors that affect the duration of survival for islet… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.
PURPOSE Pertuzumab, a recombinant humanized monoclonal antibody (2C4), binds to extracellular domain II of the HER-2 receptor and… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.
PURPOSE The role of systemic chemotherapy in the management of pancreatic endocrine carcinoma (islet cell carcinoma; PEC) is an… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
CpG Motifs as Proinflammatory Factors Render Autochthonous Tumors Permissive for Infiltration and Destruction1
In a transgenic mouse model expressing SV40 T Ag (Tag) as a de novo tumor Ag, immune surveillance fails and islet cell carcinomas… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo
The Eph family of receptor tyrosine kinases and their ligands, known as ephrins, play a crucial role in vascular development… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
A number of recent preclinical studies have sparked interest in the concept of exploiting conventional chemotherapeutic drugs as… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes.
Transgenic mice expressing the oncogene SV40 T antigen (Tag) in the insulin-producing beta cells of the pancreas develop islet… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
1996
Highly Cited
1996
Antiangiogenic therapy of transgenic mice impairs de novo tumor growth.
Angiogenesis is activated during multistage tumorigenesis prior to the emergence of solid tumors. Using a transgenic mouse model… Expand
Is this relevant?
Highly Cited
1991
Highly Cited
1991
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.
Forty-five patients with metastatic neuroendocrine tumors were treated with a regimen of etoposide 130 mg/m2/d for 3 days plus… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE